LLY
Eli Lilly and Company
LLY has the edge over PCRX overall, supported by stronger fundamentals and stronger modeled upside.
PCRX
Pacira BioSciences, Inc.
PCRX's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PCRX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Strong | |
| Strong |
PCRX's profitability, cash flow and balance sheet are currently healthy. There isn't enough data to rate its revenue.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over PCRX in the historical PE scenario, which offers more potential upside but is not a forecast.
PCRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 11x | $36.46 | — |
| Cheap | 19x | $17.40 | -52% |
| Current | 39x | $36.46 | — |
| Fair | 59x | $55.10 | +51% |
| Expensive | 166x | $156 | +328% |
Historical ranges are pointers, not guarantees.
PCRX's PE is in its fair range at 39x. If earnings grow as analysts expect, today's price would be 11x next year's earnings, in its cheap range.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over PCRX on the outlook, with more favorable revenue expectations.
PCRX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect PCRX's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over PCRX on earnings, with more consistent year-over-year improvement.
PCRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.23 | +244% |
| Q3 2026 | $0.94 | +92% |
| Q2 2026 | $0.36 | +$3.10 |
| Q1 2026 | $0.13 | +$2.37 |
| Q4 2025 | $0.16 | +$2.31 |
| Q3 2025 | $0.49 | +$2.44 |
| Q2 2025 | -$2.74 | -297% |
| Q1 2025 | -$2.24 | -248% |
| Q4 2024 | -$2.15 | -342% |
PCRX's earnings per share have fallen from their peak: $0.94 over the past year, against $3.91 in mid-2021.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over PCRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over PCRX on profitability, with a higher operating margin.
PCRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $176.7M | -1.6% |
| Q2 2026 | $192.4M | +6.2% |
| Q1 2026 | $177.4M | +5% |
| Q3 2025 | $179.5M | +6.5% |
| Q2 2025 | $181.1M | +1.7% |
| Q1 2025 | $168.9M | +1.1% |
| Q3 2024 | $168.6M | +2.8% |
| Q2 2024 | $178M | +5% |
PCRX's revenue has picked up after two years of holding roughly level: $177M last quarter, down 1.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | +9.1 points |
| Q2 2026 | 2.2% | -2.5 points |
| Q1 2026 | 3.9% | +2.7 points |
| Q4 2025 | 1.2% | N/A |
| Q3 2025 | 3.5% | +86 points |
| Q2 2025 | 4.7% | -11 points |
| Q1 2025 | 1.2% | -6.7 points |
| Q3 2024 | -83% | -94 points |
PCRX's operating margin was 13% last quarter, up 9.1 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over PCRX on cash flow, with more consistent year-over-year improvement.
PCRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $46.4M | -18% |
| Q2 2026 | $56.1M | +503% |
| Q1 2026 | $23M | -15% |
| Q4 2025 | $43.5M | +40% |
| Q3 2025 | $57M | +14% |
| Q2 2025 | $9.3M | -82% |
| Q1 2025 | $26.9M | -42% |
| Q4 2024 | $31M | -32% |
PCRX generated $169M in free cash flow over the past year, up 36% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PCRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +530K shares |
| 1 year | -8.2% | -3.6M shares |
| 3 years | -22% | -11.2M shares |
| 5 years | -10% | -4.6M shares |
| Available history | -1.6% | -683K shares |
PCRX has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $50M |
| Q4 2025 | $48.2M |
| Q3 2025 | $50M |
| Q4 2024 | — |
| Q3 2024 | — |
PCRX spent $98M buying back its own shares over the past year.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
PCRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.4x | Very low |
| Q2 2026 | 1.5x | Healthy |
| Q1 2026 | 1.9x | Healthy |
| Q4 2025 | 1.9x | Healthy |
| Q3 2025 | 1.7x | Healthy |
| Q4 2024 | 57.0x | High |
| Q3 2024 | -22.1x | Net Cash |
| Q2 2024 | -1.5x | Net Cash |
PCRX has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PCRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 77.6 | Overbought |
| Stochastic | 98.3 | Overbought |
PCRX's weekly RSI is 78 (overbought) and its Stochastic is 98 (overbought).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PCRX PE vs Healthcare Sector
| Metric | PCRX | Sector median | Relative |
|---|---|---|---|
| PE | 39x | 26x | 50% above |
| PE % | 37 | 29 | 8 pts above |
PCRX has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
PCRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $33.6 | 8.5% above |
| 20 week MA | $28.6 | 27% above |
| 50 week MA | $25.4 | 44% above |
| 100 week MA | $24.7 | 48% above |
| 200 week MA | $27.3 | 33% above |
PCRX has climbed back above all five of its weekly moving averages, and it's now 33% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
PCRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.6 | $59.2 | +33% |
| 2021 | $59.2 | $61.7 | +4.1% |
| 2022 | $61.7 | $39.7 | -36% |
| 2023 | $39.7 | $33.7 | -15% |
| 2024 | $33.7 | $19.7 | -42% |
| 2025 | $19.7 | $26.5 | +35% |
| 2026 YTD | $26.5 | $36.5 | +38% |
PCRX has the edge over LLY on returns for 2026, with the stronger performance.